Le Lézard
Classified in: Health
Subjects: TDS, FVT

Medeor Therapeutics to Present at Cowen Health Care Conference



SAN MATEO, Calif., March 8, 2018 /PRNewswire/ -- Medeor Therapeutics, Inc., a clinical-stage biotechnology company dedicated to the discovery, development and commercialization of personalized cellular immunotherapies, today announced that its President and Chief Executive Officer, Dr. Steven R. Deitcher, will present on Wednesday, March 14th at 1:00 p.m. EST at the Cowen and Company 38th annual Health Care Conference in Boston.

About Medeor Therapeutics, Inc.
Medeor Therapeutics is a clinical-stage biotechnology company dedicated to the discovery, development and commercialization of personalized cellular immunotherapies to improve outcomes in organ transplant recipients as well as non-transplant indications. Medeor's series of product candidates each comprise a unique composition of different types of hematopoietic donor-derived cells, initially based on breakthrough technologies discovered at Stanford University and exclusively licensed by Medeor. These product candidates are designed to produce mixed chimerism, the co-existence of both recipient and donor blood and immune cells in the recipient. For organ transplant recipients, mixed chimerism is intended to allow these patients to achieve donor-specific immune tolerance, prevent transplant organ loss, reduce or eliminate chronic immunosuppressive drug therapy, and thereby improve patient outcomes. For more information, visit www.medeortherapeutics.com.

Contact

Matthew Plunkett, Ph.D.
Chief Financial and Business Officer
mplunkett@medeortherapeutics.com

 

SOURCE Medeor Therapeutics, Inc.


These press releases may also interest you

22 sep 2018
NEW YORK, Sept. 22, 2018 /PRNewswire-PRWeb/ -- Statement from Communication Service for the Deaf Communication Service for the Deaf commends the United Nations, the World Federation of the Deaf and the Permanent Mission of Antigua and Barbuda....

22 sep 2018
Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of the securities of OPKO Health, Inc. from September 26, 2013 through September 7, 2018, inclusive (the "Class Period"). The...

22 sep 2018
SALT LAKE CITY, Sept. 22, 2018 /PRNewswire-PRWeb/ -- cbdMD's partnership with Global Rallycross (GRC) driver Steve Arpin officially kicks off this weekend at the 3rd Annual Nitro World Games, taking place at the Utah Motorsports Campus outside of...

22 sep 2018
TIJUANA, Mexico, Sept. 22, 2018 /PRNewswire-PRWeb/ -- Every year, thousands of American patients save millions of dollars on treatments by visiting dental clinics in Mexico. Once thought of decades ago as a poor quality cheap alternative, one clinic...

22 sep 2018
Today, Boston Scientific announced positive 12-month data from the IMPERIAL trial, the first head-to-head drug-eluting stent trial in the superficial femoral artery (SFA). Results were presented during a late-breaking clinical trial session at the...

22 sep 2018
cbdMD's partnership with Global Rallycross (GRC) driver Steve Arpin officially kicks off this weekend at the 3rd Annual Nitro World Games, taking place at the Utah Motorsports Campus outside of Salt Lake City, Utah. The...




News published on 8 march 2018 at 16:30 and distributed by: